525 bytes added ,  09:54, 14 October 2010
no edit summary
Line 52: Line 52:     
==Treatment==
 
==Treatment==
Anticholinesterase agents are the most common treament for Myasthenia Gravis. They inhibit the cholinesterase enzyme breaking down acetycholine resulting in increased levels and duration of the neurotransmitter in the synaptic cleft.
+
'''Anticholinesterase agents''' are the most common treament for Myasthenia Gravis. They inhibit the cholinesterase enzyme breaking down acetylcholine resulting in increased levels and duration of the neurotransmitter in the synaptic cleft.
Anticholinesterase agents include Pyridostigmine bromide and neostigmine.
+
Anticholinesterase agents include pyridostigmine bromide and neostigmine.
   −
Animals should be fed from a height and also have their head held in an elevated position for 5 minutes after feeding to avoid aspiration of food and the development of aspiration pneumonia.
+
Animals should be '''fed from a height''' and also have their head held in an elevated position for 5 minutes after feeding to avoid aspiration of food and the development of aspiration pneumonia.
    
Any accompanying megaoesophagus must also be treated appropriately (antibiotics and oxygen).
 
Any accompanying megaoesophagus must also be treated appropriately (antibiotics and oxygen).
Certain drugs including [[Aminoglycosides|aminoglycosides]] and antiarrhythmic drugs can intefere with neuromuscular transmission and should be avoided in myasthenia gravis patients.
+
Certain drugs including [[Aminoglycosides|aminoglycosides]] and antiarrhythmic drugs can interfere with neuromuscular transmission and should be avoided in myasthenia gravis patients.
    
The use of immunosuppressants in Myasthenia Gravis is documented but controversial, particularly in patients suffering from aspiration pneumonia.
 
The use of immunosuppressants in Myasthenia Gravis is documented but controversial, particularly in patients suffering from aspiration pneumonia.
Line 66: Line 66:  
The prognosis also depends on the underlying cause of disease which may be neoplastic.
 
The prognosis also depends on the underlying cause of disease which may be neoplastic.
 
Animals with the congenital form have a poor prognosis they do not go into remission and often deteriorate.
 
Animals with the congenital form have a poor prognosis they do not go into remission and often deteriorate.
 +
 +
==Literature Search==
 +
[[File:CABI logo.jpg|left|90px]]
 +
 +
 +
Use these links to find recent scientific publications via CAB Abstracts (log in required unless accessing from a subscribing organisation).
 +
<br><br><br>
 +
[http://www.cabdirect.org/search.html?it=any&q1=%22myasthenia+gravis%22&calendarInput=yyyy-mm-dd&occuring1=title&show=all&rowId=1&rowId=2&rowId=3&options1=AND&options2=AND&options3=AND&occuring3=freetext&occuring2=freetext&publishedend=yyyy&la=any&publishedstart=yyyy&fq=sc%3A%22ve%22&y=8&x=54 Myasthenia gravis publications]
    
==References==
 
==References==
Line 74: Line 82:     
[[Category:Antibody Mediated Autoimmune Diseases]]
 
[[Category:Antibody Mediated Autoimmune Diseases]]
[[Category:To Do - Caz]]
   
[[Category:Dog]]
 
[[Category:Dog]]
[[Category: To Do_-_Review]]
+
[[Category:Expert_Review]]
Author, Donkey, Bureaucrats, Administrators
53,803

edits